Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene.

Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP, Ellard S, Ferrer J, Hattersley AT. · 2007

Read Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. by Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP, Ellard S, Ferrer J, Hattersley AT. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc1845156.txt.

Introduction

Pearson, Hattersley and co-authors showed in 2007 that a diabetes gene can make newborns unusually large and prone to low blood sugar. The gene is HNF4A, and faults in it cause a young-onset inherited diabetes. Fetal insulin drives growth, so the team studied birth weight in families carrying these faults.

They compared 108 people from HNF4A families with 134 from families with faults in a sister gene, HNF1A. Babies carrying the HNF4A fault were a median of 790 grams heavier than relatives without it. Over half of carriers were macrosomic, meaning oversized at birth, against 13 percent of non-carriers. Passing low blood sugar after birth hit eight carrier infants and none of the non-carriers. Mouse work on the pancreas backed the fetal insulin link.

Catalog record

CREATORPearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP, Ellard S, Ferrer J, Hattersley AT.
YEAR2007
COLLECTIONPAPERS
FORMATTXT
FILE SIZE40 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC1845156

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Macrosomia and Hyperinsulinaemic Hypoglycaemia in Patients with Heterozygous Mutations in the HNF4A Gene By Ewan R Pearson, Sylvia F Boj, Anna M Steele, Timothy Barrett, Karen Stals, Julian P Shield, Sian Ellard, Jorge Ferrer, Andrew T Hattersley, Leif C Groop Published in: PLoS Medicine DOI: 10.1371/journal.pmed.0040118 ABSTRACT Background Macrosomia is associated with considerable neonatal and maternal morbidity. Factors that predict macrosomia are poorly understood. The increased rate of macrosomia in the offspring of pregnant women with diabetes and in congenital hyperinsulinaemia is mediated by increased foetal insulin secretion. We assessed the in utero and neonatal role of two key regulators of pancreatic insulin secretion by studying birthweight and the incidence of neonatal hypoglycaemia in patients with heterozygous mutations in the maturity-onset diabetes of the young (MODY) genes HNF4A (encoding HNF-4α) and HNF1A/TCF1 (encoding HNF-1α), and the effect of pancreatic deletion of Hnf4a on foetal and neonatal insulin secretion in mice. Methods and Findings We examined birthweight and hypoglycaemia in 108 patients from families with diabetes due to HNF4A mutations, and 134 patients from families with HNF1A mutations. Birthweight was increased by a median of 790 g in HNF4A-mutation carriers compared to non-mutation family members (p < 0.001); 56% (30/54) of HNF4A-mutation carriers were macrosomic compared with 13% (7/54) of non-mutation family members (p < 0.001). Transient hypoglycaemia was reported in 8/54 infants with heterozygous HNF4A mutations, but was reported in none of 54 non-mutation carriers (p = 0.003). There was documented hyperinsulinaemia in three cases. Birthweight and prevalence of neonatal hypoglycaemia were not increased in HNF1A-mutation carriers. Mice with pancreatic β-cell deletion of Hnf4a had hyperinsulinaemia in utero and hyperinsulinaemic hypoglycaemia at birth. Conclusions HNF4A mutations are associated with a considerable increase in birthweight and macrosomia, and are a novel cause of neonatal hypoglycaemia. This study establishes a key role for HNF4A in determining foetal birthweight, and uncovers an unanticipated feature of the natural history of HNF4A-deficient diabetes, with hyperinsulinaemia at birth evolving to decreased insulin secretion and diabetes later in life. INTRODUCTION Macrosomia is associated with considerable foetal and maternal morbidity [1]. Factors that predict macrosomia are still poorly understood [2]. In humans, foetal insulin secretion is one of the key determinants of foetal growth, acting mainly in the third trimester when the weight of the foetus increases greatly. This is seen in pregnant women with diabetes when foetal sensing of maternal hyperglycemia drives insulin secretion, insulin-mediated growth, and subsequent macrosomia. In addition to such environmental factors, mutations in the genes involved in insulin secretion are also known to affect birthweight. Mutations that cause hyperinsulinaemic hypoglycaemia of infancy [3–10] are associated with increased birthweight. Conversely, genes in which mutations cause neonatal diabetes [11,12] and some forms of maturity-onset diabetes of the young (MODY) [13,14] are associated with decreased birthweight. The transcription factors hepatocyte nuclear factor-4α (encoded by the HNF4A gene), and hepatocyte nuclear factor-1α (encoded by HNF1A, approved gene name TCF1) play a key role in the regulation of pancreatic insulin secretion. HNF4A and HNF1A mutations cause monogenic diabetes (MODY 1 and MODY3, respectively) due to decreased insulin secretion [15,16] and are key parts of an important β-cell network [17,18]. In the pancreas, HNF1A and HNF4A form part of a common transcriptional network, which has been proposed as an explanation of the shared pancreatic phenotype seen in patients with mutations in these genes [18]. Variants in the HNF4A pancreatic promoter have also been associated with Type 2 diabetes [19,20]. A recent study reported mildly reduced blood glucose and increased insulin levels in adult β-cell Hnf4a–deficient mice [21]. As a result of this animal study, we hypothesized that mutations in the human gene HNF4A might increase foetal insulin secretion and birthweight, and cause neonatal hyperinsulinaemia and hypoglycaemia. We therefore studied birthweight and reported hypoglycaemia in HNF4A-mutation carriers and unaffected family members. As a comparison, we also studied the families of patients with mutations in the closely associated pancreatic transcription factor HNF1A. To investigate the mechanism of neonatal hypoglycaemia and increased birthweight, we also studied foetal and neonatal mice lacking both copies of Hnf4a in the pancreas. METHODS Birthweight and Reported Hypoglycaemia in Hnf4a-Mutation Carriers One hundred and eight members (54 mutation carriers) of 15 families who had been found to have MODY due to an HNF4A mutation, were contacted. This group included 13 families where the mutation had previously been identified as well as two families, found after screening for HNF4A, where there was both neonatal hypoglycaemia and diabetes in a family member (see below). Where mutation status of an individual within a family had not previously been determined, DNA was extracted from a buccal sample. HNF4A was amplified and sequenced as previously described [22]. Birthweight and gestational age were primarily obtained by maternal recall. Birth centiles and weight were corrected to 40 wk of gestation and for male sex, according to UK 1990 reference curves [23]. In assessment of neonatal hypoglycaemia, we report here on three patients from two families described above in whom HNF4A mutations had been identified due to coexistent familial diabetes and neonatal hypoglycaemia. In addition, we contacted 101 unselected members (48 mutation carriers) of the 13 families described above who had been found previously to have MODY due to an HNF4A mutation. In babies born to mothers with diabetes during pregnancy, hypoglycaemia that did not require intravenous glucose and lasted for less than 24 h was not considered exceptional. Any other reported incidence of hypoglycaemia at birth was followed up by case-note review. An episode of hypoglycaemia was established only if venous plasma glucose of less than 2.5 mmol/l was documented. All investigations for hyperinsulinaemic hypoglycaemia were done by the referring clinician at the time of diagnosis using their local laboratory. HNF4A Mutations in Families with both Diabetes and Hypoglycaemia After our initial observations in families with known HNF4A mutations, we went on to sequence the HNF4A gene in the probands of five further families who had been referred to the Exeter Molecular Genetics Laboratory with hyperinsulinaemic hypoglycaemia, and who had at least one first-degree relative with diabetes. No monogenic cause had been found for the hypoglycaemia or diabetes in these families: three of the hypoglycaemic probands had been sequenced for activating GCK and/or KCNJ11 mutations and, in one family, members with diabetes had been sequenced for HNF1A mutations. Birthweight and Reported Hypoglycaemia in HNF1A-Mutation Carriers One hundred and thirty-four members (85 mutation carriers) from 38 families with known MODY due to an HNF1A mutation were contacted. Reported birthweight and hypoglycaemia were recorded in the same way as for HNF4A-mutation carriers. Transgenic Mice β-cell–specific Hnf4a mutations (β-Hnf4a-KO) were generated by crossing Hnf4a LoxP/LoxP mice (Jackson Laboratory, http://www.jax.org) [24] with InsPr-Cre mice, a transgenic line expressing Cre recombinase driven by the rat insulin 2 promoter [25]. Both lines were bred on a C57BL/6J genetic background. An almost complete efficiency of recombination of Hnf4a LoxP alleles in β-cells was verified by: (1) real-time PCR quantitation in RNA from isolated islets showing an 80% reduction of Hnf4a mRNA relative to control mice (Figure S1); (2) absent Hnf-4α staining in >90% β-cells on immunofluroescence analysis (unpublished data); and (3) recombination of a Rosa26LoxP-Stop-LoxP-Lacz allele in >90% of β-cells when crossed with InsPr-Cre (unpublished data). Blood insulin and glucose were

Read the complete text